0 results
0 results

Advancing Cell and Gene Therapies

White Paper

Aixial Group’s Leadership in Cell, Gene, and Immunotherapy Clinical Trials

The field of cell and gene therapies (CGT) is revolutionizing modern medicine, offering potential curative treatments for diseases previously considered untreatable, including rare genetic disorders, advanced cancers, and autoimmune diseases. Aixial Group stands as a trusted leader in CGT clinical trials, leveraging its robust expertise, cutting-edge solutions, and dedicated teams to navigate the complexities of these advanced therapies. This white paper explores the stakes of CGT today, Aixial’s role in driving innovation, and the future of this transformative sector.

The Stakes of Cell and Gene Therapies 

Cell and gene therapies present immense opportunities but also challenges. They can prevent, treat, and even cure diseases with a single dose. However, these treatments are still considered new, with uncertainties surrounding long-term effects, potential genetic modifications across generations, and immune system responses. Additionally, CGTs are expensive to develop and administer, limiting accessibility.


Despite these challenges, the CGT market is growing rapidly, valued at $5.5 billion in 2022 and projected to reach $82.4 billion by 2032. The demand underscores the need for experienced clinical research organizations (CROs) to support clinical trials and regulatory approvals.

Aixial Group’s Role in CGI Clinical Trials

Proven Expertise

Aixial Group has successfully conducted over 270 CGT clinical trials across APAC, Europe, and the Americas, spanning therapeutic areas such as oncology, hematology, rare diseases, and autoimmune disorders.

These studies range from early-phase feasibility trials to late-stage pivotal trials, showcasing Aixial’s full-spectrum clinical development expertise.

Addressing Complex Challenges

CGT trials present unique challenges, including:

  • Personalized treatment protocols
  • Complex supply chain logistics for cell-based products
  • Stringent regulatory frameworks

Aixial overcomes these challenges through:

  • Tailored Trial Design: Developing adaptive protocols suited to CGT therapies
  • Advanced Technology: Utilising eClinical tools and real-time analytics for trial optimisation
  • Regulatory Expertise: Ensuring compliance with global agencies such as the FDA, EMA, and PMDA

Specialized Teams, Aixial’s dedicated teams include:

  • Clinical scientists specializing in gene editing technologies like CRISPR and CAR-T
  • Project managers with experience in complex multi-center trials
  • Biostatisticians and data scientists adept at analyzing high-dimensional datasets

Global Reach, Local Expertise

Operating in over 25 countries, Aixial combines global capabilities with local insights, ensuring efficient site selection, patient recruitment, and regulatory compliance.

This global presence is critical for the success of CGT trials.

The Impact of CAR-T Therapy

CAR-T (Chimeric Antigen Receptor T-cell) therapy is an immunotherapy that harnesses genetically modified T cells to fight cancer. CAR-T cells recognize and bind to cancer cells more effectively, improving treatment efficiency and patient outcomes. However, CAR-T therapy requires intricate logistics, from apheresis and cell modification to reinfusion and post-treatment monitoring.

Case Studies

1. CAR-T Therapy in Hematologic Malignancies

  • Challenge: Rapid patient recruitment and complex cryopreservation logistics in a global Phase III trial.
  • Solution: Aixial implemented real-time logistics monitoring and AI-driven patient matching.
  • Outcome: Trial completed ahead of schedule, reducing operational timelines by 20%.

2. CAR-T Therapy in Hematologic Malignancies

  • Challenge: Limited patient pool hindered recruitment.
  • Solution: Aixial engaged patient advocacy groups and used targeted social media campaigns.
  • Outcome: Recruitment targets met within three months, ensuring timely trial initiation.

Future Advancements in CGT

The next generation of CGT is poised for continued innovation, focusing on:

  • Expanding CAR-T therapy into solid tumors
  • Using donor-derived immune cells like Natural Killer (NK) cells
  • Reducing manufacturing costs to improve accessibility
  • Enhancing trial efficiency through AI and biomarker-driven research

Aixial Group’s Competitive Edge

  1. Patient-Centric Approach
    • Decentralized trial models to reduce patient burden
    • Enhanced informed consent processes
    • Collaboration with patient advocacy groups
  2. Strategic Partnerships Aixial collaborates with biotech firms, academic institutions, and technology providers to drive innovation and accelerate trial timelines.
  3. Commitment to Innovation Aixial integrates novel endpoints, real-world evidence, and AI-driven trial optimization to remain at the forefront of CGT research.


Aixial Group’s expertise, innovative methodologies, and patient-centric focus establish it as a leader in CGT clinical trials. As the field evolves, Aixial continues to pioneer groundbreaking treatments, delivering hope to patients worldwide and value to industry stakeholders. With an unwavering commitment to advancing medical science, Aixial is shaping the future of cell and gene therapy research.

TO GO FURTHER